Evaluation of mTOR, NFκB, and BCL-2 Inhibitor Activity In Vitro on Diffuse Large B-Cell Lymphoma Cells

DLBCLs constitute an aggressive type of lymphoma with varied clinical, molecular and genetic features. The cells are characterized by NFkB pathway disturbances and BCL-2 and mTOR protein deregulation, which significantly inhibit apoptosis. Hence, many treatment strategies have been established to ta...

ver descrição completa

Detalhes bibliográficos

Principais autores:	Agata Majchrzak, Sylwia Mańka, Barbara Cebula-Obrzut, Aleksandra Mędra, Paweł Robak, Damian Mikulski, Magdalena Witkowska
Formato:	Artigo
Idioma:	Inglês
Publicado em:	MDPI AG 2026-02-01
Colecção:	Current Issues in Molecular Biology
Assuntos:	BCL-2 inhibitors diffuse large B-cell lymphoma mTOR inhibitors NFκB inhibitors
Acesso em linha:	https://www.mdpi.com/1467-3045/48/2/229
Tags:	Adicionar Tag Sem tags, seja o primeiro a adicionar uma tag!